NCT07204938
A Long-Term Study of Navenibart in Participants With Hereditary Angioedema
Enrolling by Invitation
PHASE3Ages 12+InterventionalPreventionAstria Therapeutics, Inc.
~145 participants
Updated 2026-07-30 on ClinicalTrials.gov
What's tested:navenibart
At a glance
Recruiting sites
0 of 40 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of treatment-emergent adverse events (TEAEs)
Measured over Day 1 through Month 48
Conditions
Where it's being run
40 sites across 25 statesUnited Kingdom6
Israel4
California3
Colorado2
Italy2
Japan2
Poland2
Spain2
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Incidence of treatment-emergent adverse events (TEAEs)Day 1 through Month 48